Eyestem is a cell therapy company founded by a top-class management team consisting of clinical trials, cell therapy, and ophthalmology experts. It also boasts a world-class advisory board and has built collaborations with pioneers and leaders in the space. Its lead candidate-Eyecyte-RPE for age-related macular degeneration will enter human trials shortly. Its long-term vision is to democratize access to cell therapy by creating a create scalable cell therapy platform to treat incurable diseases.